Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
New data illuminates research in cancer therapy
July 28th, 2005
Data on cancer therapy are outlined in reports from the United States and Japan. Study 1: The anti-cancer agent ixabepilone has produced promising results in a phase I clinical trial. "The epothilones are a novel class of microtubule-stabilizing agents," oncologists in the United States explained. "Ixabepilone (BMS-247550; NSC 710428) is a semisynthetic analog of the natural product epothilone B." S.H. Zhuang and colleagues at the National Cancer Institute "conducted a Phase I study by administering ixabepilone to patients as a 1-hour intravenous infusion daily for 3 consecutive days every 21 days." "Twenty-six...
Source: Women's Health Weekly (2005-07-28)
|
